Managing risks in drug discovery: reproducibility of published findings
In spite of tremendous advances in biopharmaceutical science and technology, the productivity of pharmaceutical research and development has been steadily declining over the last decades. The reasons for this decline are manifold and range from improved standard of care that is more and more difficu...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 February 2016
|
| In: |
Naunyn-Schmiedeberg's archives of pharmacology
Year: 2016, Jahrgang: 389, Heft: 4, Pages: 353-360 |
| ISSN: | 1432-1912 |
| DOI: | 10.1007/s00210-016-1216-8 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s00210-016-1216-8
|
| Verfasserangaben: | Aimo Kannt, Thomas Wieland |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662955847 | ||
| 003 | DE-627 | ||
| 005 | 20230426154255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190408s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00210-016-1216-8 |2 doi | |
| 035 | |a (DE-627)1662955847 | ||
| 035 | |a (DE-599)KXP1662955847 | ||
| 035 | |a (OCoLC)1341207932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kannt, Aimo |e VerfasserIn |0 (DE-588)113944431X |0 (DE-627)89717691X |0 (DE-576)182360288 |4 aut | |
| 245 | 1 | 0 | |a Managing risks in drug discovery |b reproducibility of published findings |c Aimo Kannt, Thomas Wieland |
| 264 | 1 | |c 17 February 2016 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.04.2019 | ||
| 520 | |a In spite of tremendous advances in biopharmaceutical science and technology, the productivity of pharmaceutical research and development has been steadily declining over the last decades. The reasons for this decline are manifold and range from improved standard of care that is more and more difficult to top to inappropriate management of technical and translational risks along the R&D value chain. In this short review, major types of risks in biopharmaceutical R&D and means to address them will be described. A special focus will be on a risk, i.e., the lack of reproducibility of published information, that has so far not been fully appreciated and systematically analyzed. Measures to improve reproducibility and trust in published information will be discussed. | ||
| 650 | 4 | |a Reproducibility | |
| 650 | 4 | |a Research and development | |
| 650 | 4 | |a Risk management | |
| 650 | 4 | |a Technical risk | |
| 650 | 4 | |a Translational risk | |
| 700 | 1 | |a Wieland, Thomas |d 1960-2025 |e VerfasserIn |0 (DE-588)1033445908 |0 (DE-627)741233215 |0 (DE-576)381043339 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Naunyn-Schmiedeberg's archives of pharmacology |d Berlin : Springer, 1873 |g 389(2016), 4, Seite 353-360 |h Online-Ressource |w (DE-627)254638309 |w (DE-600)1462940-9 |w (DE-576)074531433 |x 1432-1912 |7 nnas |a Managing risks in drug discovery reproducibility of published findings |
| 773 | 1 | 8 | |g volume:389 |g year:2016 |g number:4 |g pages:353-360 |g extent:8 |a Managing risks in drug discovery reproducibility of published findings |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00210-016-1216-8 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190408 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1033445908 |a Wieland, Thomas |m 1033445908:Wieland, Thomas |d 60000 |d 65400 |e 60000PW1033445908 |e 65400PW1033445908 |k 0/60000/ |k 1/60000/65400/ |p 2 |y j | ||
| 998 | |g 113944431X |a Kannt, Aimo |m 113944431X:Kannt, Aimo |d 60000 |d 65400 |e 60000PK113944431X |e 65400PK113944431X |k 0/60000/ |k 1/60000/65400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1662955847 |e 3421001286 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 19.10.05"],"pubHistory":["1.1873 -"],"id":{"eki":["254638309"],"issn":["1432-1912"],"zdb":["1462940-9"]},"recId":"254638309","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Archives of pharmacology"},{"title":"Archiv für experimentelle Pathologie und Pharmakologie"},{"title":"Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie"},{"title":"Naunyn-Schmiedebergs Archiv für Pharmakologie und experimentelle Pathologie"},{"title":"Naunyn-Schmiedebergs Archiv für Pharmakologie"}],"title":[{"title":"Naunyn-Schmiedeberg's archives of pharmacology","title_sort":"Naunyn-Schmiedeberg's archives of pharmacology"}],"origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1873","dateIssuedDisp":"1873-","publisher":"Springer"}],"part":{"text":"389(2016), 4, Seite 353-360","extent":"8","pages":"353-360","volume":"389","year":"2016","issue":"4"},"disp":"Managing risks in drug discovery reproducibility of published findingsNaunyn-Schmiedeberg's archives of pharmacology","language":["eng"]}],"origin":[{"dateIssuedDisp":"17 February 2016","dateIssuedKey":"2016"}],"title":[{"subtitle":"reproducibility of published findings","title":"Managing risks in drug discovery","title_sort":"Managing risks in drug discovery"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1662955847","id":{"doi":["10.1007/s00210-016-1216-8"],"eki":["1662955847"]},"note":["Gesehen am 08.04.2019"],"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Aimo Kannt, Thomas Wieland"]},"person":[{"roleDisplay":"VerfasserIn","display":"Kannt, Aimo","role":"aut","family":"Kannt","given":"Aimo"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Wieland, Thomas","given":"Thomas","family":"Wieland"}]} | ||
| SRT | |a KANNTAIMOWMANAGINGRI1720 | ||